MBrace Therapeutics
Focus: MBrace Therapeutics is a micro-cap oncology biotech founded in 2022, specializing in phage-display antibody discovery and antibody-drug conjugates (ADCs). The company is currently in early-stage development with a minimal employee base.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Employees
1-50
Open Jobs
0
About MBrace Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow MBrace Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Clinical Trials (1)
NCT07145255Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Phase 1/2Help build intelligence for MBrace Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.